64岁及以上成人格列美脲转格列吡嗪的血糖控制与就诊风险
在Kaiser Permanente Southern California的回顾性队列研究中,625名64至110岁使用格列美脲的成员中,472人转换为格列吡嗪、153人继续使用。转换后6至12周糖化血红蛋白无差异;转换组在4个月内因低血糖急诊或住院风险更低(OR 0.49),支持老年患者优选短效磺脲类。
要点
- 格列美脲转格列吡嗪后6至12周糖化血红蛋白无差异。
- 转换组4个月内低血糖相关急诊或住院风险更低(OR 0.49)。
- 结果支持Beers标准:老年患者优选短效磺脲类。
核心结论
- 64岁及以上患者从长效磺脲类转换为短效磺脲类后血糖控制无变化,且4个月时急诊或住院利用率更低。
研究设计与样本
- 回顾性队列研究,纳入625名64至110岁Kaiser Permanente Southern California成员,均在2023年3月15日至2024年3月14日期间配发格列美脲。
- 转换在2024年3月索引日期后于配药药房完成,472人转换为格列吡嗪,153人继续使用格列美脲。
主要发现
- 索引日期后6至12周,继续使用格列美脲者平均HgbA1c为7.8(SD 1.3),转换者平均HgbA1c为7.8(SD 1.1),两者无差异。
- 调整年龄和合并症后,2个月内因低血糖急诊或住院风险无显著差异(OR 0.68,95% CI 0.34至1.36)。
- 转换者在4个月内因低血糖急诊或住院风险低于继续使用格列美脲者(OR 0.49,95% CI 0.29至0.85)。
关键数值与推荐
- Beers标准声明:老年患者优选短效磺脲类而非长效磺脲类。
临床怎么用
- 对64岁及以上使用长效格列美脲的老年患者,可考虑转换为短效格列吡嗪以维持血糖控制并降低低血糖相关急诊或住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Short-acting sulfonylureas are preferred over long-acting sulfonylureas due to reduced risk of hypoglycemia in older adults. Whether older patients can be transitioned from long-acting to short-acting sulfonylureas with equivalent glycemic control while experiencing fewer emergency department (ED) visits or hospitalizations due to hypoglycemia is unknown. We investigated whether the conversion of long-acting glimepiride to short-acting glipizide led to equivalent glycemic control and whether it was associated with reduced ED or hospital utilization. METHODS: We conducted a retrospective-cohort study of 625 Kaiser Permanente Southern California members between ages 64 and 110 years old dispensed glimepiride between 03/15/2023 and 03/14/2024. The conversion to glipizide occurred at the dispensing pharmacy after the index date in March 2024. The co-primary outcomes were to determine whether glycemic control could be maintained with the conversion of one sulfonylurea to another based on a follow-up HgbA1c at 6 to 12-weeks post-conversion while reducing ED utilization or hospitalization for patients within 2 and 4-months of the index date. RESULTS: Of 625 patients eligible for the intervention, 472 converted to glipizide and 153 remained on glimepiride. Results 6 to 12-weeks post-index date showed no difference in HgbA1c between those who remained on glimepiride (mean = 7.8; SD = 1.3) and those who converted (mean = 7.8; SD = 1.1). For risk of ED or hospitalization from hypoglycemia, no significant difference was found within 2 months (OR: 0.68, 95% CI: 0.34, 1.36) after adjusting for age and comorbidities. Those who converted to glipizide had lower risk of ED or hospitalization within 4-months (OR: 0.49, 95% CI: 0.29, 0.85) than patients remaining on glimepiride. CONCLUSION: Patients 64 years and older converted from long-acting to short-acting sulfonylureas had no change in glycemic control, and lower rates of ED or hospital utilization at 4-months were observed. This paper reaffirms the Beers Criteria statement that shorter-acting sulfonylureas are preferred over longer-acting sulfonylureas.
引用
- Lee EA, Lin JC, Kanter MH, et al. Glycemic Control and Utilization Risk With the Conversion of Glimepiride to Glipizide in Adults 64 Years and Older at an Integrated Health Care System. J Am Geriatr Soc. 2026. PMID: 42095749. doi:10.1111/jgs.70494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。